rel perform pharmaceut giant
report discuss
compar view merck
recommend buy rate
compani estim
target price merck co
base
merck perform
merck roa roi roe stood
respect ytd
perform stock
perform
perform
pfizer roa roi roe
respect ytd
perform stock
 perform
perform
merck ep ttm compar
pfizer ep ttm forward
price-to-earnings merck compar
pfizer forward price-to-earnings
merck profit margin
compar
pfizer revenu compar
merck revenu
recommend buy rate
stock upsid potenti
higher merck current
ep roe better compar merck
rule
leader leagu drug
compani namemerck co pfizer inc tickermrkpfecurr stock ratingbuybuylast year ratingbuybuyindustri viewoverweightoverweightpositivepositivepric year apr week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth merck vs april
prescript medicin vaccin biolog therapi anim
health care product view overweight stock target price
provid upsid potenti
merck full year revenu increas due launch
keytruda zepati bridion strong perform anim health
busi full year revenu reflect increment revenu merck
unabl fulfil order certain product certain market due
cyber-attack unfavor effect revenu
non-i-o therapi also perceiv great opportun product
lynpraza co-develop co-commerci colleagu
astrazeneca pharma revenu increas
compar anim health care revenu
compar
merck revenu declin compar
decreas revenu due effect
gener competit zetia vytorin cubicin declin product
within diversifi brand includ nasonex dulera inhal aerosol
merck intern revenu increas compar
increas revenu due growth keytruda
zepati higher revenu vaccin due termin
spmsd joint ventur higher revenu anim health product
merck continu bring innov patient physician
expand focu oncolog advanc develop
program keytruda therapi lynparza parp inhibitor
co-develop co-commerci astrazeneca receiv key
merck gross margin increas sg expens increas
 expens decreas non-gaap effect tax
rate net incom declin compar previou
year merck plan invest year capit project includ
maintain buy rate stock base perform
estim revenu ep
estim revenu ep
pfizer inc research base global biopharmaceut compani engag
discoveri develop manufactur healthcar product
global portfolio includ medicin vaccin well consum
healthcar product view overweight stock target price
provid upsid potenti
pfizer full year revenu decreas compar
decreas reflect unfavor impact result one
less sell day intern market slight oper
decreas unfavor impact foreign exchang
pfizer innov health busi revenu increas y/i
compar increas driven continu
growth key brand includ ibranc eliqui global increas
also due addit xtandi revenu due acquisit
mediv septemb
pfizer essenti health busi revenu declin y/i
compar revenu neg
impact oper declin peri-lo product due expect
declin pristiq well lyrica europ revenu also
neg impact oper declin steril inject
sip portfolio due continu shortag product
hospira
cog decreas si expens
 expens decreas oper margin
compar previou year net incom increas
due one time tax benefit relat re-measur defer
partnership astella submit prosper data fda
seek expand label non-metastat set number
urologist activ prescrib xtandi continu grow reach all-tim
high compar zytiga
maintain buy rate stock base perform
estim revenu ep revenu
estim ep estim
merck co inc global health care compani deliv innov health
solut prescript medicin vaccin biolog therapi
anim health product pfizer inc research-bas global biopharmaceut
compani engag discoveri develop manufactur
healthcar product portfolio includ medicin vaccin well
merck oper manag product basi includ four oper
segment anim health allianc
segment manag commerci oper two busi
segment innov ih essenti eh
merck anim health global leader research develop
manufactur sale veterinari medicin pfizer major revenu
come manufactur sale biopharmaceut product
fastest grow segment merck anim health grew
compar segment full year
revenu also grew compar wherea
fastest grow segment recent quarter innov
ih grew oper y/i compar
ih revenu increas oper y/i
compar
merck consid peer oncolog product market
merck anim health segment also contribut strong growth revenu
segment
merck revenu year increas due strong growth keytruda
oncolog product merck therapi use
treatment cancer pfizer revenu year also increas due
strong growth oncolog product ibranc xtandi eliqui
total oncolog revenu merck grew y/i
oncolog revenu merck full year grew y/i
oncolog revenu grew y/i
full year grew y/i merck grow faster
rate seem reach satur stage
merck oncolog product keytruda grew y/i grew
oncolog product ibranc grew y/i
grew y/i keytruda grow
faster rate
decemb compani come updat
main oncolog product merck announc fda accept review
supplement bla keytruda treatment adult pediatr
patient refractori pmbcl relaps two prior
line therapi announc updat progression-fre surviv
result phase trial reinforc clinic benefit
ibranc combin letrozol
merck revenu year increas compar
total revenu compar
decreas y/i
merck cog declin due decreas materi product
compar merck cog declin
cog
cog
mrqcog mrqcog sale merck vs april
pfizer cog decreas compar
decreas due favor impact sale
global oper carri higher cost sale product
cog increas compar
due unfavor impact hospira acquisit pfizer
cog increas
merck gross margin compar
increas gross margin due lower acquisit divestiture-rel
cost restructur cost merck gross margin increas
due decreas cog
gross margin
gross margin
pfizer gross margin compar
increas due decreas cog gross margin decreas
due increas cog
merck net incom declin compar
decreas due increas tax rate
compar previou year quarter increas tax rate result
net loss quarter compar previou year quarter
merck net margin decreas
net margin merck
net margin pfizer
pfizer net incom compar
increas due one time tax benefit relat re-
measur defer tax-liabl pfizer net margin decreas
merck ep compar estim ep
pfizer ep compar estim ep
sinc last one year merck stock price declin went
april pfizer stock price posit growth past
one year stock under-perform compar
merck roa roi roe stood respect
ytd perform stock perform
perform experienc
declin sale major brand keytruda bridion zepati
lynparza gain market share global market expect low
mid-singl digit growth revenu maintain buy rate
tp
pfizer roa roi roe respect ytd
perform stock perform
perform finish solid year despit
neg revenu impact due
divest hospira infus system also saw continu growth
emerg market oper maintain buy
rate tp
incom statement forecast
result overview
guidanc conclus
non- reconcili
per share item ratio
product perform develop
valuat consensu perform
strengthen oncolog busi lead growth
maintain buy rate downgrad target price
deriv tp base estim ep
forward look price-to-earnings give
upsid potenti
apart discuss base estim
number factor keytruda sale recov decent
pace progress lynparza add
strength oncolog busi strong global launch
zepati growth anim busi primarili driven
continu strength companion anim busi includ
bravecto growth rumin busi recent
fda approv keytruda lynparza
metastat lung cancer keytruda remain lead
treatment option across i-o non-i-o therapi fda
approv lynparza use patient germlin brca-
mutat metastat breast cancer
previous treat chemotherapi either
neoadjuv adjuv metastat set
see great opportun lynparza compani
co-develop co-commerci colleagu
approv broader ovarian cancer label
current launch new metastat breast cancer
revenu number littl lower
estim better cost manag beat
adjust ep estim
compani namemerck compani inc new tickermrkstock ratingbuyunchangedindustri viewoverweightpositivepric week week volum volum ep gin gin ttm per share growth profit ttm ttm incom ttm earn growth yoy n/acrispidearavindra except ep crispidea merck vs april
revenu quarter increas
compar pharma revenu
increas compar
total revenu anim health care
quarter increas compar
net loss quarter declin
compar ep
compar non-gaap ep
compar
japanes ministri labor welfar
approv keytruda treatment patient
radic unresect urotheli carcinoma progress
cancer chemotherapi
geograph wise revenu
declin compar
sale increas compar
price-to-earnings drop averag till
averag price-to-earnings average stdev
average stdev price-to-earnings
went averag current
experienc declin sale major
brand keytruda bridion zepati lynparza
gain market share global market
expect low mid-singl digit growth revenu
maintain rate buy tp
stock price histori date high obsolet date obsolet move move share statist averag volum averag volum share held held share short short share short prior dividend split forward annual dividend forward annual dividend trail annual dividend trail annual dividend year averag dividend pay-out dividend date jan ex-dividend date dec last split factor new per last split date feb inform merck vs april
incom statement month end month end month month end month month revenu total- total revenu gross selling/general/admin expens research depreciation/amortization- interest expens incom net operating- unusu expens oper expens total- total oper oper interest incom expens net non-operating- loss sale assets- incom incom minor equiti affiliatesnet incom extra account changediscontinu operationsextraordinari itemnet prefer dividendsincom avail common excl extra incom avail common incl extra basic weight averag sharesbas ep exclud extraordinari itemsbas ep includ extraordinari itemsdilut adjustmentdilut weight averag dilut ep exclud extraordinari dilut ep includ extraordinari itemsdividend per share common stock primari gross dividend common stocknet incom stock base comp expensebas ep stock base comp expsensedilut ep stock base comp expensedepreci supplementaltot special itemsnorm incom taxeseffect special item incom taxesincom tax ex impact special itemsnorm incom taxesnorm incom avail commonbas normal epsdilut normal actual annual estim annual actual quarterli merck vs april
oper activ compar cash
oper activ compar declin cash provid oper
activ reflect payment relat settlement feder incom tax issu payment
relat format collabor astrazeneca payment made
merck relat settlement world-wide keytruda patent litig
provid invest activ compar
cash invest activ compar chang cash due
lower purchas secur invest higher proce sale secur
invest lower use cash acquisit busi
use financ activ compar cash
financ activ compar increas cash use financ
activ due proce issuanc debt higher purchas treasuri stock
lower proce exercis stock option partial off-set lower payment debt
income/start amortization- defer non- chang work oper capit invest item invest financ total dividend issuanc retir stock issuanc retir debt financ foreign exchang net chang merck vs april
merck end quarter increas revenu impact new tax
legisl billion provision charg anim health
product continu show strong perform remain core growth
driver merck
revenu
quarter
compar
revenu quarter increas compar
pharma revenu increas
compar total revenu anim health care
quarter increas compar
cog quarter
increas
compar
compar
revenu reflect increment revenu due vaccin
sale european countri part sanofi pasteur msd
spmsd vaccin joint ventur termin decemb
total revenu quarter also includ partial
replenish dose gardasil human papillomaviru
vaccin recombin borrow center diseas
control prevent cdc
total revenu compar also reflect favor
impact due time shipment japan prior year
revenu unfavor affect lost sale
certain market relat cyber-attack occur june
cog quarter increas compar
gross margin compar
non-gaap gross margin compar
sg expens quarter declin compar
previou year quarter decreas expens due lower
acquisit divestiture-rel cost
 expens declin compar
declin due lower in-process research develop
ipr impair charg partial off-set higher expens relat
busi develop transact clinic develop spend
invest earli drug develop
result overview
incom expens net incom compar
expens non-gaap incom expens net
incom compar expens
effect incom tax rate compar
non-gaap effect incom tax rate
compar
net loss quarter increas compar
ep compar
non-gaap ep compar
full year total revenu increas compar
full year revenu reflect increment revenu
pharma revenu increas compar
anim health care revenu compar
increas revenu due launch keytruda zepati
bridion well posit perform merck anim health busi
higher revenu pneumovax adempa well anim health
product also contribut revenu growth
merck unabl fulfil order certain product certain market due
cyber-attack unfavor effect revenu
 revenu declin compar
sale increas
compar
decreas revenu due effect gener competit
zetia vytorin cubicin declin product within diversifi brand
includ nasonex dulera inhal aerosol revenu
increas due growth keytruda zepati higher revenu
vaccin due termin spmsd joint ventur higher
revenu anim health product
incom tax rate
compar
incom tax rate
compar
 revenu
declin compar
sale
increas compar
result overview
gross margin compar
increas gross margin due lower acquisit divestiture-rel
cost restructur cost
sg expens increas compar increas
reflect higher administr cost includ cost associ vaccin
busi previous part spmsd vaccin joint ventur
remedi cost relat cyber-attack higher promot expens
relat product launch
 expens decreas compar
declin reflect lower ipr impair charg restructur cost
incom expens net expens compar
expens non-gaap incom expens net
expens compar expens
incom expens net reflect favor impact foreign exchang
gain sale secur
effect tax rate compar
includ unfavor impact provision charg relat
tax legisl non-gaap effect tax rate compar
net incom declin compar
gaap ep compar non-gaap ep
compar
total cash invest includ cash
cash equival short-term invest long-term
recent enact tax legisl improv merck financi
flexibl invest sustain long-term valu creat opportun merck
plan invest year capit project includ
gross margin
compar
increas
gross margin due
lower acquisition-
restructur cost
total cash
invest
cash cash
equival short-
term invest
long-term
segment perform
merck oper two busi segment pharmaceut
pharmaceut pharmaceut product includ therapeut
prevent agent gener sold prescript treatment human
pharma revenu increas compar
pharma revenu increas
compar
increas revenu due signific growth keytruda merck
continu launch keytruda multipl new indic global strong
momentum treatment patient nsclc contribut significantli
keytruda overal growth approv first-
total pharmaceut segment revenu
compar segment intern revenu
compar
primari women health
total revenu zetia market countri outsid unit
state ezetrol vytorin market outsid unit state inegi
atozet market certain countri outsid unit state
adempa declin fy compar
revenu declin due lower volum price zetia
vytorin unit state result gener competit
zetia/vytorin revenu quarter declin
compar zetia/vytorin revenu
compar
pursuant collabor bayer ag bayer merck lead
commerci right adempa countri outsid america
bayer lead right america includ unit state
revenu adempa compar
pharma revenu
increas
compar
increas revenu
due signific growth
keytruda
revenu zetia
vytorin atozet
declin
compar
segment perform
total product revenu compar
total intern revenu compar
total revenu januvia janumet quarter increas
compar total product revenu declin
compar includ favor
effect foreign exchang
total product revenu declin due on-going price pressur
partial off-set continu volum growth global
revenu product januvia janumet
compar total intern revenu
compar
gener medicin women health
total revenu nuvar declin compar
includ favor effect foreign exchang
revenu declin due lower revenu unit state lower
demand europ
total revenu implanon/nexplanon increas
compar increas due higher price
volum growth unit state
total revenu januvia
janumet
quarter increas
compar
total revenu
nuvar declin
compar
includ
favor effect
increas
compar
revenu product nuvar implanon/nexplanon
follistim aq compar total
intern revenu product compar
hospit specialti
zepati revenu quarter increas compar
product revenu increas
compar product revenu increas due
higher sale europ unit state japan follow product
launch intern market
segment perform
total revenu isentress isentress hd declin
compar total product revenu declin
compar
revenu product decreas due lower demand unit
state europ due competit pressur
revenu compar
total intern revenu product compar
total revenu quarter increas compar
total revenu compar
bridion revenu increas compar
product revenu increas
compar increas product revenu
due strong global demand particularli unit state
noxafil revenu increas compar
product revenu increas
compar increas revenu due higher
demand price unit state volum growth europ
invanz revenu quarter increas compar
product revenu increas
compar increas due higher revenu
unit state result higher price partial off-set
lower demand also higher demand brazil
canciduss revenu declin compar
product revenu declin
compar declin product revenu
due gener competit certain european market
total revenu
hd declin
compar
revenu product
bridion increas
compar
revenu product
cancidu declin
compar
compar
segment perform
cubicin revenu declin compar
product revenu declin
compar composit patent
cubicin expir june product revenu declin result
gener competit
revenu product declin
compar total intern revenu
product compar
total revenu quarter declin compar
total revenu compar
remicad revenu declin compar
product revenu declin
compar
simponi revenu increas compar
product revenu increas
compar includ favor effect
foreign exchang increas revenu due higher demand
total oncolog revenu quarter compar
total revenu compar
revenu product keytruda increas
compar product revenu increas
compar increas revenu
due volum growth market particularli unit state europ
japan product continu launch multipl new indic
revenu keytruda emend temodar increas
compar total intern
revenu compar
revenu product
remicad declin
compar
product
revenu declin
compar
revenu product
keytruda increas
compar
segment perform
total revenu singulair nasonex dulera
compar total product revenu
compar
singulair revenu quarter declin compar
product revenu declin
compar product declin due lower
volum japan result gener competit
nasonex revenu quarter declin compar
product revenu declin
compar revenu product declin due
gener competit
dulera revenu quarter declin compar
product revenu declin
compar declin revenu due lower sale
unit state reflect on-going competit price pressur well
revenu product compar
total intern revenu
compar
total revenu cozaar arcoxia fosamax
compar total product revenu
compar
total revenu gardasil/gardasil proquad/m-m-r ii/varivax
pneumovax rotateq zostavax compar
total product revenu
compar
singulair revenu
quarter declin
compar
dulera revenu
quarter declin
compar
total revenu
rotateq
zostavax
compar
segment perform
revenu product gardasil/gardasil increas
compar
product revenu increas compar
increas revenu due higher sale europ result
termin spmsd joint ventur well higher demand asia
proquad/m-m-r ii/varivax revenu quarter compar
product revenu
compar
pneumovax revenu increas compar
product revenu increas
compar increas revenu due
higher demand price unit state well higher sale
europ result termin spmsd joint ventur
rotateq revenu quarter compar
product revenu increas
compar increas revenu due higher
sale europ result termin spmsd joint ventur
zostavax revenu decreas compar
product revenu compar
revenu declin due lower demand
unit state reflect approv competitor vaccin receiv
preferenti recommend acip octob
prevent shingl zostavax
revenu product compar
total intern revenu
compar
pharmaceut sale quarter decreas
y/i compar revenu
compar
revenu product
increas
compar
revenu product
zostavax decreas
compar
sale quarter
decreas
y/i compar
segment perform
other segment includ anim health
anim includ pharmaceut vaccin product prevent
treatment control diseas major farm companion anim
speci anim health sale affect competit frequent
introduct gener product
total revenu quarter increas compar
revenu compar
increas revenu due higher sale companion anim
product larg due growth bravecto line product kill flea
tick dog cat week higher revenu rumin
product swine product poultri product also contribut growth
merck expand focu oncolog advanc develop
program keytruda therapi receiv key regulatori
approv busi develop transact
decemb fda accept review supplement bla
keytruda treatment adult pediatr patient refractori
pmbcl relaps two prior line therapi
merck announc pivot phase trial investig
keytruda combin pemetrex alimta cisplatin
carboplatin first-lin treatment patient metastat non-
squamou non-smal cell lung cancer nsclc met dual primari
endpoint overal surviv os progression-fre surviv
merck announc pivot phase trial investig
keytruda second-lin treatment patient advanc gastric
gastroesophag junction adenocarcinoma meet primari
endpoint overal surviv patient whose tumor express
total revenu
anim health care
quarter increas
compar
decemb
fda accept review
supplement bla
keytruda
treatment adult
pediatr patient
refractori pmbcl
relaps
two prior line
therapi
merck european organ research treatment cancer
eortc announc phase trial investig
keytruda monotherapi surgic resect high-risk melanoma met
primari endpoint recurrence-fre surviv base interim
analysi follow review independ data monitor
committe result significantli longer recurrence-fre surviv
japanes ministri labor welfar approv keytruda
treatment patient radic unresect urotheli carcinoma
progress cancer chemotherapi
fda approv lynparza use patient germlin brca-mut
metastat breast cancer previous treat
chemotherapi either neoadjuv adjuv metastat
ertugliflozin investig oral inhibitor
review eu investig fixed-dos combin
sitagliptin ipragliflozin review japan
investig pediatr hexaval combin vaccin
ipv-hib-hepb review fda develop
approv commerci joint ventur merck
sanofi
investig rvsv-zebov ebola vaccin candid
studi larg scale phase clinic trial
januari merck announc fda accept review two
nda doravirin nda includ data doravirin once-daili
tablet use combin antiretrovir agent use
doravirin lamivudin tenofovir disoproxil fumar once-daili
fixed-dos combin singl tablet complet regimen
japanes ministri
labor
keytruda
treatment patient
radic
carcinoma
progress cancer
announc fda
accept review two
nda doravirin
lynparza olaparib oral parp inhibitor approv certain
type ovarian breast cancer selumetinib oral potent
select inhibitor mek part mitogen-activ protein kinas
mapk pathway develop multipl cancer type
announc
also known apec
inactiv varicella zoster viru vaccin develop
prevent herp zoster merck complet phase trial autolog
hematopoiet cell transplant patient anoth phase trial patient
solid tumor malign undergo chemotherapi hematolog
select non-narcot orally-administ
agonist develop treatment refractori chronic cough merck
plan initi phase clinic trial first half
februari merck announc stop protocol also
known apec studi phase studi evalu verubecestat mk-
investig small molecul inhibitor beta-sit amyloid
precursor protein cleav enzym peopl prodrom
merck made strateg decis discontinu develop
investig combin regimen
treatment chronic hcv infect
merck announc fda approv steglatro ertugliflozin
tablet oral sodium-glucos cotransport inhibitor fixed-
dose combin steglujan ertugliflozin sitagliptin fixed-dos
combin segluromet ertugliflozin metformin hydrochlorid
help improv glycem control adult type diabet
fda european commiss approv prevymi letermovir once-
daili tablet oral use inject intraven infus indic
prevent cytomegaloviru cmv infect diseas adult cmv-
seroposit recipi allogen hematopoiet stem cell transplant
fda approv isentress raltegravir merck integras inhibitor use
combin antiretrovir agent treatment
newborn patient birth four week age weigh least kg
inhibitor use
combin
antiretrovir agent
treatment
newborn patient
birth four week
age weigh least
tabl show pipelin product develop differ phase merck
phase reviewcanc keytruda advanc solid tumor ovarian prostatebacteri infect relebactam imipenem/cilastatin octob molecular entities/vaccineschron cough keytruda breast octob colorect novemb esophag decemb gastric may eu head neck novemb eu hepatocellular may nasopharyng april renal octob small-cel lung may lynparza pancreat decemb prostat april selumetinib thyroid june mellitu sitagliptin ipragliflozin ertugliflozin ertugliflozin sitagliptin ertugliflozin metformin mellitu keytruda breast octob colorect novemb esophag decemb gastric may eu head neck novemb eu hepatocellular may renal octob small-cel lung may pancreat decemb prostat april thyroid june mellitu sitagliptin ipragliflozin japan ertugliflozin eu ertugliflozin sitagliptin eu ertugliflozin metformin eu hiv infect vaccin march doravirin doravirine/lamivudine/tenofovir disoproxil fumar pneumoconjugatevaccin failur vericiguat septemb hexaval combin vaccin zoster inactiv vzv vaccin decemb supplement file keytruda relaps refractori primari mediastin bcell lymphoma pmbcl broader approv ovarian cancer eu hiv doravirin decemb doravirin lamivudin tenofovir disoproxil fumar june develop collabor develop current hold investig pediatr hexaval combin vaccin develop approv commerci partnership merck sanofi novemb fda issu respect compani work provid addit data request fda merck vs april
merck expect revenu includ
posit impact foreign exchang
ep expect non-
ep expect includ neg
impact foreign exchang
non-gaap tax rate expect
non-gaap oper expens expect increas y/i due increas
merck continu bring innov patient physician
expand focu oncolog advanc develop program
keytruda pembrolizumab therapi lynparza olaparib
parp inhibitor co-develop co-commerci astrazeneca
total revenu increas compar
increas due launch keytruda zepati bridion posit
perform merck anim health busi segment
profit grew compar due higher revenu
favor effect product mix
revenu
non-gaap tax rate
expect
continu bring
innov patient
physician
expand focu
gross margin
compar
oper
incom
compar
gross margin compar oper
incom compar roa roe
respect
cash oper activ declin compar
net chang cash merck plan
invest year capit project includ
non- reconcili
non- reconcili
non- reconcili
gross margin increas reduc cog compar
revenu growth ttm compar
oper incom compar
ep declin compar
ratio revenu margin margin inc margin rate margin turnov averag asset leverag averag equiti year averag averag averag year averag averag averag year averag averag averag growth growth ex sale /sale /net incom ratio profit marginsprofitabilityrevenu growth oper incom growthep growth merck vs april
mrqgross mrqcog mrqoper mrqsg mrqnet mrqr sale merck vs april
invest flow
sale
mrqyoy growth revenu growthoper incom growthep mrqfinanci mrq ratio growth yoy oper growth yoy free growth mrqreturn mrqreturn mrqcapex salescap ex salesfre /sale merck vs april
per share item ratio
fiscal per per per per share cash-flow per per valu per book per end stock end stock equiti asset invest capit capit joel greenblatt margin margin margin equiti total debt total pay-out sale account convers rate incom incom margin itemsquarterli item merck vs april
balanc sheet item
outstand equival market properti plant properti plant issuanc prefer issuanc chang merck vs april
price-to-earnings drop averag till averag price-to-earnings average
stdev average stdev
price-to-earnings went averag current
breakdown share held share held float held institut hold direct holder form kenneth willi weir mirian robert adam michael juli richard institut holdersholdershar report outvaluevanguard group inc wellington manag compani capit world price row associ northern trust jp morgan top mutual fund holdersholdersharesd report outvaluevanguard total stock market vanguard spdr etf incom fund america washington mutual investor vanguard institut fund-institut vanguard specialized-health vanguard/wellington fund ishar fidel competit
developmentsfda grant prioriti review merck supplement biolog licens applic sbla keytruda pembrolizumab treatment advanc cervic cancerth food drug administr fda accept new supplement biolog licens applic sbla grant prioriti review keytruda pembrolizumab compani therapi first file accept prioriti review grant therapi cervic cancer regulatori submiss accept fda keytruda eisai co ltd merck enter global strateg oncolog collabor lenvima lenvatinib mesyl eisai co ltd merck agre upon strateg collabor world-wide co-develop co-commerci lenvima lenvatinib mesyl oral avail tyrosin kinas inhibitor discov eisai agreement eisai merck develop commerci lenvima jointli monotherapi combin merck therapi keytruda pembrolizumab lynparza olaparib receiv posit eu chmp opinion platinum-sensit relaps ovarian cancerastrazeneca merck announc committe medicin product human use chmp european medicin agenc adopt posit opinion recommend market author lynparza olaparib tablet mg twice daili use mainten therapi patient platinum-sensit relaps high grade epitheli ovarian fallopian tube primari periton cancer complet respons partial respons platinum-bas chemotherapi lynparza recommend treatment set regardless patient brca mutat statu fda approv lynparza olaparib germlin brca-mut metastat breast cancerth food drug administr fda approv lynparza olaparib use patient deleteri suspect deleteri germlinebrca-mut gbrcam human epiderm growth factor receptor metastat breast cancer previous treat chemotherapi neoadjuv adjuv metastat settingmarch merck vs april
ytd stock perform
vs
price-to-earnings ratio ttm
industri
averag
gross margin ttm
industri
averag
actual vs price-to-earnings ratio ttm price-to-earnings high last yr price-to-earnings last yr beta price sale ttm price book mrq price ttm price free ttm errorerrorerror own dividend yield dividend yield year average dividend year growth rate pay-out ratio ttm sale mrq vs qtr yr sale ttm vs ttm yr sale yr growth rate sale yr growth rate ep mrq vs qtr yr ep ttm vs ttm yr ep yr growth rate ep yr growth rate capit spend yr growth rate lt debt equiti mrq total debt equiti mrq interest coverag ttm gross margin ttm gross margin yr average ebitd margin ttm ebitd yr average oper margin ttm oper margin yr average pre-tax margin ttm pre-tax margin yr average net profit margin ttm net profit margin yr average effect tax rate ttm effect tax rate yr average return asset ttm return asset yr average return invest ttm return invest yr average return equiti ttm return equiti yr average revenue/employe ttm net income/employe ttm receiv turnov ttm inventori turnov ttm asset turnov ttm manag effect effici performancevalu ratio dividend growth rate ratio profit merck vs april
consensu view analyst trend stock
growth forecast
lower
 forecast
forward price-to-earnings
lower compar
annual usdgrowth high day day day estim avgfive-year growth forecast comparisonmrkindustri avg avgprice/earn yield consensu view analyst trend stock
averag earn estim
current quarter compar
next quarter
sale growth current
quarter estim
compar next
estimatescurr analyst estimatethi estim estimatepast ep growthprice/earningsobsoleteobsoleteobsoleteobsoletepeg ratioobsoleteobsoleteobsoleteobsoleteconsensu ep day day day day ep last last daysn/an/an/an/adown last dayserrorerrorerrorerrordown last dayscurr growth ratescurr surprisescurr analyst recommend
stock price went januari decemb
stock price went februari trade around
share come high trade level
march share trade around march trade around
stock went februari fell level oct
stock price increas compar went sinc octob
experienc declin sale major brand keytruda bridion zepati
lynparza gain market share global market expect low mid-singl digit growth
revenu maintain rate buy tp
incom statement forecast
product pipelin develop
guidanc conclus
non- reconcili
per share item ratio
balanc sheet item
product perform develop
valuat consensu perform
fda approv xeljanz strengthen inform immunolog franchis
maintain buy rate upgrad tp
estim non-gaap ep forward
earn multipl provid upsid
potenti estim revenu growth
base estim follow factor strong
growth major brand includ ibranc eliqui lyrica ih
xeljanz robust growth biosimilar eh segment
continu uptak inflectra/remsima develop market
europ launch
growth xtandi allianc revenu
partnership astella submit prosper
data fda seek expand label non-
number urologist activ prescrib xtandi continu
grow reach all-tim high
compar zytiga
term expect impact
expect impact remain
rang improv
less
miss revenu estim slightli due continu
product howev strong bottom-lin growth pfe
adjust ep beat estim number
compani namepf inc tickerpfestock ratingbuyunchangedindustri viewoverweightpositivepric feb week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth except ep crispidea merck vs april
pfizer revenu stood compar
increas y/i
increas reflect favor impact foreign exchang
partli off-set oper declin
net incom quarter compar
net margin exclud tax benefit
quarter compar
ep quarter compar
compar eh
revenu declin oper y/i
compar
oper due februari divestitur
seen consist increas price strong
growth net margin pfe blockbust like ibranc xtandi
eliqui etc gain traction world-wide expect
growth increas maintain buy
rate target price
price-to-earnings show signific volatil around mean due
price chang price-to-earnings fell standard
deviat occas due grow ep
declin stock price prove better year
maintain strong price-to-earnings back constant price
increas due recent decreas price price-to-earnings
revert back mean level
oper margin roa roi roe
ttm basi respect gaap
ep
stock price histori date high obsolet date obsolet move move share statist averag volum averag volum share held held share short short share short prior dividend split forward annual dividend forward annual dividend trail annual dividend trail annual dividend year averag dividend pay-out dividend date ex-dividend date feb last split factor new per last split date jul inform merck vs april
incom statement item month end month end month end month end month end month end month end month end month end month end month end revenu total- total revenu gross selling/general/admin expens research interest expens incom net operating- unusu expens oper expens total- total oper oper interest incom expens net non-operating- loss sale net- incom incom minor equiti affiliates- net incom extra account change- discontinu operations- extraordinari item- net prefer dividends- incom avail common excl extra incom avail common incl extra basic weight averag shares- basic ep exclud extraordinari items- basic ep includ extraordinari items- dilut adjustment- dilut weight averag dilut ep exclud extraordinari dilut ep includ extraordinari items- dividend per share common stock primari gross dividend common stock- net incom stock base comp expense- basic ep stock base comp expsense- dilut ep stock base comp expense- depreci supplemental- total special items- normal incom taxes- effect special item incom taxes- incom tax ex impact special items- normal incom taxes- normal incom avail common- basic normal eps- dilut normal actual annual estim annual actual quarterli merck vs april
 short term short term account receiv trade receiv other- total receiv total prepaid expenses- current asset total current property/plant/equip total goodwil intang long term long term asset total account accru note payable/short term current port lt debt/capit current liabil total current long term capit leas obligations- total long term total defer incom minor liabil total redeem prefer stock total- prefer stock non redeem common stock addit paid-in retain earn accumul treasuri stock equiti total total liabil sharehold share out common stock primari issue- total common share actual annual actual quarterli balanc sheet item merck vs april
net cash provid oper activ compar increas
reflect time receipt custom payment vendor ordinari cours busi
partial off-set increas benefit plan contribut
net cash use invest activ compar chang
due decreas cash use acquisit fro increas invest
activ includ dividend receiv invest
net cash use financ activ compar increas
primarili due issuanc long-term debt cash dividend paid
cash equival compar
month end month end month end month end month end month end month end month end income/start work oper invest item invest dividend retir stock retir debt financ exchang chang interest paid tax paid merck vs april
stood
compar
increas y/i
quarter increas
y/i
compar
deliv strong quarterli result oper revenu growth
exclud hsp infus system period led strong growth
major brand newly-acquir product includ xtandi saw strong
increas margin doubl digit growth decreas cost well
adjust ep quarter beat estim
pfizer revenu stood compar
increas y/i increas reflect favor impact
foreign exchang partli off-set oper declin
cog increas y/i compar
gross margin quarter compar
 expens quarter decreas y/i compar
si expens quarter
increas y/i compar
amort expens quarter increas y/i
compar increas primarili due
inclus amort expens quarter
net incom
quarter
compar
net margin
quarter
compar
ep
quarter
compar
deduct quarter compar
increas y/i increas due increas interest
expens decreas royalti incom loss earli retir debt
increas partli off-set lower asset impair charg loss
re-measur
ebit quarter compar
increas y/i ebit increas increas revenu decreas
cost oper margin quarter compar
net incom quarter compar
net margin exclud tax benefit quarter compar
ep quarter compar
total revenu
compar
decreas
cog
compar
si expens
flat y/i
compar
total revenu compar
decreas y/i decreas reflect unfavour impact
result one less sell day intern market
slight oper decreas unfavor impact foreign
exchang
cog compar decreas
y/i decreas primarili due
favor impact sale global oper carri
higher cost sale product
recognit synergi relat cost-reduction/product initi
non-recurring unfavor impact acquir hospira
inventori measur fair valu acquisit date
amort turn relat inventori
favor impact foreign exchang favor off-set
hedg gain
favor chang product mix includ oper declin sip
portfolio favor attribut product lost exclus
partial off-set
inventori loss overhead cost relat period
puerto rico plant oper increment cost date
result recent hurrican puerto rico
si expens flat y/i compar
primarili due
non-recurr allow doubt trade account receiv
result unfavor develop distributor
record
lower advertis promot field forc expens reflect
benefit cost-reduct product initi
lower spend certain product primarili prevnar
 expens
compar
decreas
favor impact sale global oper
lower spend viagra due loss exclus decemb
partli off-set
xeljanz well biosimilar primarili relat launch
increas charit contribut includ charit
contribut pfizer foundat organ provid grant
invest fund support organ social entrepreneur
effort improv healthcar deliveri
 expens compar
decreas y/i decreas due
lower expens due discontinu global clinic
develop program bococizumab non-recurr
associ close-out cost
partli off-set
increas cost associ oncolog program primarili clinic trial
spend mediv asset
lower develop fund credit primarili relat
discontinu global clinic develop program bococizumab
increas cost associ difficil vaccin program
initi phase clinic studi march
expens result may agreement sangamo
develop commerci gene therapi program hemophilia
increas cost associ late stage develop program includ
xtandi talazoparib tanezumab
amort expens compar
increas increas due amort expens
pre-tax associ identifi intang asset
acquir mediv anacor partial off-set asset becam
fulli amort end estim use live favor
impact februari sale
ebit increas y/i compar
increas due higher percent decreas oper expens
decreas revenu oper margin
compar
net incom compar
increas due one time tax benefit relat re-measur
defer tax-liabl ep compar
compar
increas
ebit
y/i compar
oper margin
compar
net incom
compar
gaap ep
compar
manag commerci oper two distinct busi
innov ih pfizer essenti eh
ih revenu increas oper y/i compar
increas driven continu growth key
brand includ ibranc eliqui global addit xtandi revenu
 result septemb acquisit mediv well
lyrica xeljanz primarili
increas partli off-set lower revenu enbrel develop
european market due continu biosimilar competit also viagra
 primarili due wholesal destock advanc anticip
competit gener begin decemb
ih revenu increas oper y/i compar
increas driven continu growth key brand
includ ibranc eliqui global addit xtandi revenu
result septemb acquisit mediv well lyrica
xeljanz primarili
global prevnar revenu declin oper
 prevnar revenu declin primarili due
continu declin revenu adult indic due smaller remain
catch opportun partial off-set increas govern purchas
compar pediatr indic
oper y/i
compar
oper
 prevnar
primarili due
continu declin
revenu adult
indic due
opportun
prevenar revenu
oper
prevenar revenu intern market increas oper
primarili due favor overal impact time increas
volum associ govern purchas certain emerg market
pediatr indic compar year-ago quarter well
inclus prevenar addit nation immun program certain
emerg market adult pediatr indic
cog increas primarili driven increas royalti expens
mostli relat ibranc partial off-set favor chang product mix
si increas y/i primarili driven non-recurr
allow doubt trade account receiv result unfavor
develop distributor record lower spend
certain product primarili prevnar viagra lost
exclus decemb partial off-set addit
invest across sever key product primarili eucrisa ibranc xeljanz
decreas expens y/i primarili reflect
discontinu global clinic develop program bococizumab
partial off-set increas cost associ difficil vaccin
program initi phase clinic studi march oncolog
program primarili clinic trial spend legaci mediv asset
eh revenu declin oper y/i compar
oper due februari
divestitur revenu also neg impact
oper declin peri-lo product primarili due expect declin
pristiq well lyrica develop europ eh revenu also
neg impact oper declin steril inject
sip portfolio primarili due continu legaci hospira
product shortag
declin partial off-set oper growth biosimilar
primarili inflectra develop europ
eh revenu declin oper y/i compar
revenu also neg impact
oper declin peri-lo product primarili due expect declin
pristiq well lyrica develop europ eh revenu also
neg impact oper declin steril inject
sip portfolio primarili due continu legaci hospira
product shortag
decreas
expens y/i
discontinu
global clinic
bococizumab
oper y/i
compar
oper due
februari
divestitur
oper y/i
compar
eh revenu emerg market grew oper fro
primarili driven oper growth legaci establish
product portfolio oper growth sip portfolio exclud
period eh revenu emerg market grew
cog decreas y/i primarili due favor impact
sale higher cost sale eh product net
decreas royalti expens lower volum mainli driven steril
inject pharmaceut sip portfolio primarili due legaci hospira
product shortag favor impact foreign exchang
si expens decreas y/i primarili due favor
impact sale lower advertis promot field forc
expens reflect benefit cost-reduct product initi
well lower expens associ product recent lost market
exclus partial off-set increas spend biosimilar primarili
relat launch inflectra
 expens decreas y/i primarili due decreas
spend biosimilar close-out certain post-market clinic trial
favor impact sale
eh revenu emerg
oper
growth legaci
portfolio
oper growth
sip portfolio
y/i
primarili due
decreas spend
biosimilar close-out
certain post-
favor impact
sale
merck kgaa
announc fda
btd avelumab
combin inlyta
axitinib treatment-
nave patient
announc fda
indic expand
use sutent includ
adjuv treatment
adult patient high
risk recurr renal
product pipelin develop
oper biopharmaceut busi emd serono
canada merck kgaa announc fda grant
breakthrough therapi design btd avelumab combin
inlyta axitinib treatment-nav patient advanc renal cell
btd base preliminari evalu clinic data javelin
renal global phase studi assess safeti efficaci
avelumab combin inlyta treatment treatment-nav
patient advanc rcc btd design acceler develop
review potenti medicin seriou condit preliminari
clinic evid indic therapi may demonstr substanti
improv current avail therapi one clinic
signific endpoint second btd grant avelumab
inlyta approv monotherapi treatment advanc rcc
failur one prior system therapi
novemb merck kgaa announc phase
javelin gastric trial meet primari endpoint superior overal
surviv single-ag avelumab compar physician choic
chemotherapi trial investig avelumab third-lin treatment
unresect recurr metastat gastric gastroesophag junction
therapeut regimen regardless program death
safeti profil avelumab consist observ overal
javelin clinic develop program javelin gastric data
examin effort better understand result also
submit present upcom medic congress outcom
javelin gastric impact current avelumab
sutent sunitinib malat novemb announc fda
approv new indic expand use sutent includ
adjuv treatment adult patient high risk recurr renal cell
product pipelin develop
bosulif bosutinib decemb announc fda
approv supplement new drug applic snda expand
indic bosulif includ adult patient newlydiagnos chronic
cml snda review approv fda prioriti review
acceler approv program base molecular cytogenet
continu approv indic may conting upon verif
confirm clinic benefit on-going long-term follow trial
bosulif first approv septemb treatment
adult patient chronic acceler blast phase ph cml
resist intoler prior therapi
steglatro ertugliflozin steglujan ertugliflozin sitagliptin
segluromet ertugliflozin metformin hydrochlorid decemb
merck known msd outsid canada announc
fda approv steglatro ertugliflozin tablet oral sodium-glucos
cotransport inhibitor adjunct diet exercis improv
glycem control adult type diabet mellitu
sitagliptin tablet adjunct diet exercis improv glycem
control adult type diabet mellitu treatment
ertugliflozin sitagliptin appropri segluromet ertugliflozin
metformin hydrochlorid tablet adjunct diet exercis
improv glycem control adult type diabet mellitu
adequ control regimen contain ertugliflozin metformin
patient alreadi treat ertugliflozin metformin
januari committe medicin product human use
chmp european medicin agenc recommend approv
steglatro steglujan segluromet european commiss
review chmp recommend decis expect
announc fda
snda expand
indic bosulif
newlydiagnos
merck announc
fda approv
tablet oral sodium-
inhibitor
adjunct diet
exercis improv
glycem control
adult type
result
reinforc clinic
benefit ibranc
combin letrozol
announc fda
twice daili xeljanz
mg daili
treatment adult
patient activ
product pipelin develop
progression-fre surviv result phase trial
reinforc clinic benefit ibranc combin letrozol
data present san antonio breast cancer
symposium sabc demonstr combin ibranc plu
letrozol reduc risk diseas progress improv
median one year compar letrozol plu placebo
month ci vs month ci use
initi treatment postmenopaus women estrogen receptor-
updat post-hoc analysi includ median follow-up
three year longest date phase studi
inhibitor overal surviv data yet matur time updat
xeljanz/xeljanz xr tofacitinib decemb announc
fda approv xeljanz mg twice daili xeljanz xr extend releas
mg daili treatment adult patient activ psoriat
arthriti inadequ respons intoler
methotrex disease-modifi antirheumat drug dmard
xeljanz/xeljanz xr first janu kinas jak inhibitor approv
fda moder sever rheumatoid arthriti activ
decemb announc fda extend prescript
drug user fee act pdufa date three month snda xeljanz
review treatment adult patient moder sever
activ ulcer coliti uc demonstr inadequ respons
loss respons intoler corticosteroid azathioprin
mercaptopurin tumor necrosi factor inhibitor therapi
fda determin addit review time necessari due
inform recent submit updat pdufa goal date
decis fda june fda confirm snda
subject gastrointestin drug advisori committe meet
schedul march discuss efficaci safeti data well
benefit-risk consider uc snda
product pipelin develop
decemb announc initi phase
program once-daili inhibitor evalu efficaci
safeti treatment moderate-to-sever atop dermat ad
phase trial random double-blind placebo-control parallel-
group studi evalu patient year older moderate-
to-sever ad trial particip randomli assign receiv mg
daili mg daili placebo
primari endpoint proport patient achiev investig
global assess iga score point improv
proport patient least greater chang baselin
eczema area sever index easi score treatment durat
week durat phase studi
week safeti follow-up period option enter long-term extens
studi week design phase trial base phase
result present congress european academi
dermatolog venereolog septemb
talazoparib decemb announc phase
embraca trial patient germlin inherit
superior patient treat talazoparib investig oral
dualmechan poli ribos polymeras parp inhibitor taken
daili compar patient receiv physician choic standard
median month ci patient treat
talazoparib month ci treat
reduct risk diseas progress addit proport
patient achiev complet partial respons object respons rate
talazoparib group twice control arm
talazoparib vs chemotherapi ci
embraca data present oral present
announc initi
phase program
once-daili
evalu efficaci
safeti
treatment moderate-
announc
compar safeti
efficaci studi pf-
eu met primari
product pipelin develop
potenti biosimilar rituximab januari pfizer
announc phase reflect compar safeti
efficaci studi versu mabthera rituximab-eu met
primari endpoint demonstr equival overal respons rate
firstlin treatment patient low tumor burden follicular
lymphoma develop potenti biosimilar
rituxan rituximab-u /mabthera
one arm phase javelin medley trial pdx-nave pdx-
experienc patient use concurr dose utomilumab avelumab
combin manag safeti profil earli signal
efficaci insuffici support advanc utomilumab avelumab
combin phase trial exploratori analys potenti identifi
patient segment may benefit particular combin continu
detail result trial present futur medic meet
result on-going studi involv utomilumab includ tripl
combin avelumab utomilumab agonist
solid tumor inform next step utomilumab
one arm
medley trial pdx-nave
pdx-experienc
dose utomilumab
avelumab
ertugliflozin
ertugliflozin
xeljanz xr
adjunct diet exercis improv glycem control adult type diabet
mellitu develop collabor merck
adjunct diet exercis improv glycem control adult type diabet
mellitu adequ control regimen contain ertugliflozin
metformin patient alreadi treat ertugliflozin metformin
develop collabor merck
adjunct diet exercis improv glycem control adult type diabet
mellitu treatment ertugliflozin sitagliptin appropri
develop collabor merck
treatment adult patient newly-diagnos chronic phase philadelphia chromosome-
posit ph cml develop collabor avillion
xeljanz mg twice daili xeljanz xr extend releas mg daili
treatment adult patient activ psoriat arthriti inadequ
respons intoler methotrex disease-modifi antirheumat drug
biosimilar remicad infliximab elig indic refer product
adjuv treatment adult patient high risk recurr renal cell carcinoma follow
nephrectomi surgic remov cancer kidney
extended-releas tablet cv once-daili therapi manag neuropath pain
associ diabet peripher neuropathi manag post-herpet
approv japan ibranc combin endocrin therapi treatment
hr inoper recurr breast cancer
approv japan treatment cur unresect merkel cell carcinoma
develop collabor merck kgaa germani
approv eu treatment adult patient metastat merkel cell
carcinoma develop collabor merck kgaa germani
approv eu treatment dult patient relaps refractori bcell
approv eu prophylact vaccin activ immun prevent
invas diseas caus neisseria meningtidi serogroup individu year
age older
approv japan treatment non-smal cell lung cancer
approv eu xeljanz combin methotrex treatment
moder sever activ rheumatoid arthriti adult patient respond
inadequ intoler one disease-modifi antirheumat
drug xeljanz given monotherapi case intoler methotrex
treatment methotrex inappropri
treatment patient alk-posit metastat non-smal cell lung cancer
previous treat one inhibitor
potenti biosimilar filgrastim
potenti biosimilar herceptin trastuzumab
treatment adult patient moder sever activ ulcer coliti
treatment adult patient activ psoriat arthriti
pan-human epiderm growth factor receptor tyrosin kinas inhibitor first-lin treatment
patient advanc non-smal cell lung cancer estim glomerular filtrat rate egfr activ
mutat develop collabor sfj
next gener tyrosin kinas inhibitor treatment patient alk-posit metastat
non-smal cell lung cancer previous treat one inhibitor
prophylact vaccin activ immun prevent clostridium difficil coliti
potenti biosimilar rituxan rituximab
potenti biosimilar avastin bevacizumab
potenti biosimilar humira adalimumab
pan-selectin inhibitor treatment vaso-occlus crisi hospit individu sickl cell
diseas licens
pan-selectin inhibitor treatment vaso-occlus crisi hospit individu sickl cell
diseas licens
long-act hgh-ctp treatment growth hormon defici children develop
collabor opko
long-act hgh-ctp treatment growth hormon defici adult develop
collabor opko
oral parp inhibitor treatment metastat castrat resist prostat cancer
oral parp inhibitor treatment patient germlin breast cancer suscept gene brca
anti-nerv growth factor monoclon antibodi treatment pain develop
collabor lilli
monoclon antibodi inhibit combin inlyta axitinib tyrosin kinas
inhibitor first-lin treatment advanc renal cell carcinoma develop
collabor merck kgaa germani
monoclon antibodi inhibit first-lin treatment stage iiib/iv non-smal cell lung
cancer develop collabor merck kgaa germani
monoclon antibodi inhibit treatment stage iiib/iv non-smal cell lung cancer
progress platinum-contain doublet develop collabor
monoclon antibodi inhibit treatment platinum-resistant/refractori ovarian
cancer develop collabor merck kgaa germani
monoclon antibodi inhibit first-lin treatment ovarian cancer
develop collabor merck kgaa germani
monoclon antibodi inhibit mainten treatment first-lin set
patient urotheli cancer develop collabor merck kgaa germani
monoclon antibodi inhibit mainten treatment advanc metastat
gastric/ gastro-esophag junction cancer develop collabor merck
monoclon antibodi inhibit treatment local advanc squamou cell carcinoma
head neck develop collabor merck kgaa germani
adjuv treatment renal cell carcinoma develop collabor sfj
treatment advanc breast cancer collabor allianc foundat trial llc
treatment high-risk earli breast cancer collabor german breast group
treatment hr earli breast cancer collabor allianc foundat trial llc
treatment non-metastat castrat resist prostat cancer
treatment non-metastat high risk hormone-sensit prostat cancer
treatment metastat hormone-sensit prostat cancer
guidanc conclus
financi guidanc reflect full year contribut consum healthcar
continu expect decis regard strateg altern
consum healthcar made financi guidanc also assum
gener competit lyrica june
expect
franchis continu
strengthen
recent approv
xeljanz psoriat
adjust sale revenu
effect tax rate adjust incom
incom
oper margin
roa
roi roe ttm
basi
respect
gaap ep
revenu estim
adjust dilut ep anticip share repurchas total
finish solid year despit neg revenu
impact due divest hospira infus system also saw
continu growth emerg market oper
innov health strong year driven major product ibranc revenu
grew oper year expect inform
immunolog franchis continu strengthen recent approv
xeljanz psoriat arthriti
essenti health revenu growth continu suffer product strong
oper growth emerg market biosimilar continu eh
segment expect impact
oper margin roa roi roe ttm basi
respect ep
non- reconcili
non- reconcili
non- reconcili
gross margin ttm basi compar due decreas cost
revenu growth ttm compar
ep growth ttm compar due increas net margin
ratio revenu margin margin inc margin rate margin turnov averag asset leverag averag equiti year averag averag averag year averag averag averag year averag averag averag growth growth ex sale /sale /net incom ratio profit marginsprofitabilityrevenu growth oper incom growthep growth merck vs april
mrqgross mrqcog mrqoper mrqnet mrqsg mrqr sale merck vs april
invest flow
sale
mrqfinanci mrqreturn mrqreturn mrqyoy growth revenu growthoper incom growthep mrq ratio growth yoy oper growth yoy free growth mrqcapex salescap ex salesfre /sale merck vs april
fiscal per per per per share cash-flow per per valu per book per end stock end stock equiti asset invest capit capit joel greenblatt margin margin margin equiti total debt total pay-out sale account convers rate incom incom margin itemsquarterli item merck vs april
outstand equival market properti plant properti plant issuanc prefer issuanc chang merck vs april
price-to-earnings volatil around mean due price chang price-to-earnings fallen standard
deviat occas due grow ep declin stock price prove
better year maintain strong price-to-earnings back constant price increas due recent
decreas price price-to-earnings revert back mean level
breakdown share held insid share held institut mutual fund float held institut mutual fund institut hold direct holder form ian frank freda john anthoni alexand loretta dougla institut holdersholdershar report outvalueblackrock vanguard group inc america jp morgan northern trust wellington manag compani geod capit manag price row associ top mutual fund holdersholdersharesd report outvaluevanguard total stock market vanguard spdr etf vanguard institut fund-institut vanguard/windsor ishar fidel select sector spdr fund-health vanguard -valu mf seri trust i-mf valu competit
developmentspf receiv posit chmp opinion hematolog medicin mylotarg bosulif inc announc committe medicin product human use chmp european medicin agenc ema adopt posit opinion recommend two hematolog medicin grant market author european union eu mylotarg gemtuzumab ozogamicin combin daunorubicin cytarabin grant posit opinion treatment patient age year previous untreat de novo acut myeloid leukemia aml except acut promyelocyt leukemia apl bosulif bosutinib grant posit opinion treatment adult newli diagnos chronic phase philadelphia chromosome-posit chronic myelogen leukemia ph cml chmp opinion medicin review separ european commiss ec pfizer announc updat european market author applic sutent sunitinib adult patient high risk recurr renal cell carcinoma inc announc committe medicin product human use chmp european medicin agenc ema recommend expand use sutent sunitinib includ adjuv treatment adult patient high risk recurr renal cell carcinoma rcc follow nephrectomi surgic remov cancer kidney chmp recommend bind taken consider european commiss ec current approv adjuv treatment option avail patient non-metastat rcc high risk recurr european union eu pfizer receiv breakthrough therapi design fda oral inhibitor treatment patient moderate-to-sever atop dermat inc announc once-daili oral janu kinas inhibitor receiv breakthrough therapi design food drug administr fda treatment patient moderate-to-sever atop dermat ad phase program initi decemb first trial atop dermat efficaci safeti jade global develop program eu japan author accept regulatori submiss review third-gener inhibitor lorlatinib inc announc food drug administr fda accept grant prioriti review compani new drug applic lorlatinib lorlatinib investig anaplast lymphoma kinas tyrosin kinas inhibitor tki treatment patient -posit metastat non-smal cell lung cancer nsclc previous treat one tki european medicin agenc japan medic devic agenc also accept market applic use lorlatinib februari merck vs april
stock
under-perform last
year return
price/sal ratio
lower industri average
gross margin
impress
industri
actual vs price-to-earnings ratio ttm price-to-earnings high last yr price-to-earnings last yr beta price sale ttm price book mrq price ttm price free ttm errorerrorerror own dividend yield dividend yield year average dividend year growth rate pay-out ratio ttm sale mrq vs qtr yr sale ttm vs ttm yr sale yr growth rate sale yr growth rate ep mrq vs qtr yr ep ttm vs ttm yr ep yr growth rate ep yr growth rate capit spend yr growth rate lt debt equiti mrq total debt equiti mrq interest coverag ttm gross margin ttm gross margin yr average ebitd margin ttm ebitd yr average oper margin ttm oper margin yr average pre-tax margin ttm pre-tax margin yr average net profit margin ttm net profit margin yr average effect tax rate ttm effect tax rate yr average return asset ttm return asset yr average return invest ttm return invest yr average return equiti ttm return equiti yr average revenue/employe ttm net income/employe ttm receiv turnov ttm inventori turnov ttm asset turnov ttm manag effect effici performancevalu ratio dividend growth rate ratio profit merck vs april
consensu view analyst trend stock
forward price-to-earnings
well
pfe avgfive-year growth forecast usdgrowth high day day day estim comparisonpfeindustri avg avgprice/earn yield merck vs april
consensu view analyst trend stock
earn growth
estim
revenu growth estim
adjust ep estim
estimatescurr analyst estimatethi estim estimatepast ep growthpeg ratioobsoleteobsoleteobsoleteobsoleteconsensu ep day day day day ep revisionsn/an/an/an/aup last last daysn/an/an/an/adown last daysn/an/an/an/a current surprisescurr growth rate analyst recommend
stock came high feb due shrink revenu struggl
bestsel like lipitor celebrex etc
stock given total return last month
stock reach high jan consist increas price
stock given total return last year
stock shown uptrend sinc given total return last year
stock saw heavi movement may high volum reach time high jan
seen consist increas price strong growth net margin pfe blockbust like ibranc
xtandi eliqui etc gain traction world-wide expect growth increas
maintain buy rate target price
crispidea financi inform servic firm focus provid equiti research portfolio manag
person wealth manag brokerag servic inform servic side provid commun
consult research servic host client
crispidea track limit number compani sector strive provid qualiti insight straight
forward analysi object creat long-term wealth moder low risk crispidea leverag
larg number in-hous extern expert oper within industri strong financi oper
strateg background
detail visit www crispidea com contact
